Keytruda (pembrolizumab)

pCPA File Number: 21928

Negotiation Status:

Concluded with an LOI

Indication(s):

Advanced or metastatic renal cell carcinoma (RCC) in adult patients with no prior systemic therapy for metastatic RCC (in combination with Lenvima)

Sponsor/Manufacturer:

Merck Canada Inc.

CDA-AMC Project Number:

PC0268-000

pCPA Engagement Letter Issued:

2022-10-21

Negotiation Process Concluded:

2023-05-12